https://www.biospace.com/retrophin-announces-corporate-name-change-to-travere-therapeutics-inc
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc. - BioSpace
Nov 16, 2020 - Retrophin Inc., (NASDAQ: RTRX) today announced that the Company has changed its global corporate name to Travere Therapeutics, Inc. This new name reflects the...
corporate name changetravere therapeuticsretrophinannouncesinc
https://www.biospace.com/retrophin-to-report-fourth-quarter-and-full-year-2017-financial-results
Retrophin to Report Fourth Quarter and Full Year 2017 Financial Results - BioSpace
Sep 17, 2018 - Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018 after the close...
fourth quarter
https://www.biospace.com/retrophin-to-report-fourth-quarter-and-full-year-2014-financial-results
Retrophin To Report Fourth Quarter And Full Year 2014 Financial Results - BioSpace
fourth quarter
https://www.biospace.com/retrophin-to-report-third-quarter-2019-financial-results
Retrophin to Report Third Quarter 2019 Financial Results - BioSpace
Oct 16, 2019 - The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
2019 financial resultsthird quarterretrophinreport
https://www.biospace.com/retrophin-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference
Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference - BioSpace
Jan 7, 2019 - Retrophin, Inc. today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San...
j p morgan
https://www.biospace.com/retrophin-to-present-at-upcoming-investor-conferences-nov-11-2020
Retrophin to Present at Upcoming Investor Conferences - Nov 11, 2020 - BioSpace
Nov 12, 2020 - Retrophin, Inc. announced that Company management will present at the following upcoming virtual investor conferences in November and December
nov 11 2020investor conferencesretrophinpresentupcoming
https://www.biospace.com/retrophin-announces-pivotal-phase-3-fort-study-of-fosmetpantotenate-in-pkan-opens-enrollment-to-pediatric-patients
Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to...
Sep 17, 2018 - Retrophin, Inc. (NASDAQ:RTRX) today announced that the independent Data Monitoring Committee (DMC) for the pivotal Phase 3 FORT Study, which is evaluating...
https://www.biospace.com/retrophin-reports-third-quarter-2019-financial-results
Retrophin Reports Third Quarter 2019 Financial Results - BioSpace
Oct 31, 2019 - Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN
2019 financial resultsthird quarterretrophinreports